Please provide your email address to receive an email when new articles are posted on . A 37-year-old woman presents with oral lesions consistent with pemphigus vulgaris and is treated with prednisone ...

Pemphigus vulgaris is a chronic blistering disease. Clinically it is characterized by painful intra-epidermal bullae and superficial vesicles involving both the skin and mucosal areas. The diagnosis ...

Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed. At 1 year, ...

Presents the case of a pregnant woman with erosions and desquamation with erythematose areas only on the gingiva due to Pemphigus vulgaris. Gingival lesions comprise severe desquamative or erosive ...

DSG3-CAART is designed to selectively target the cause of mucosal pemphigus vulgaris. The Food and Drug Administration (FDA) has granted Fast Track designation to DSG3-CAART (desmoglein 3 chimeric ...

Pemphigus refers to a group of skin disorders that cause blistering and sores on the skin or mucous membranes of the mouth, nose, throat or genital region. The onset of disease is usually in ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus is ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not ...

Researchers compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. Pemphigus, an autoimmune disease mediated by B cells and which causes painful ...